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Summary 
 
The aim of this guidance document is to provide a short and user-friendly support to genetic 
testing laboratories. It is based on internationally harmonised basic concepts and terminology 
for quality assurance and control (QA/QC). Relevant terms of the International Organisation 
for Standardisation (ISO) and the International Vocabulary of Metrology (VIM) are explained 
and references to other expert texts are provided. The document includes discussion and 
clarification of several often misunderstood issues. It takes into account the current scientific 
knowledge and the existing technological capabilities. This document may be revised, when 
appropriate, to take into account progress in science and technology and constitutes a 
deliverable of the NoE EuroGentest. 
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Glossary 
CE  Marking according to the EU IVD Directive 
CDC  Centers for Disease Control and Prevention (USA) 
CITAC  Co-operation on International Traceability in Analytical Chemistry 
CRM  Certified Reference Material 
CLSI  Clinical Laboratory Standards Institute 
DNA Deoxyribonucleic acid 
EC European Commission 
EEC European Economic Community 
EQA External Quality Assessment 
EU  European Union 
FDA  Food and Drug Administration (USA) 
GB  Great Britain 
GUM ISO Guide to the Expression of Uncertainty in Measurement, ISO, Geneva 1995 
IFCC  International Federation of Clinical Chemistry and Laboratory Medicine 
IQC  Internal Quality Control 
ILAC  International Laboratory Accreditation Cooperation 
IRMM  Institute for Reference Materials and Measurements, Joint Research Centre, European 
Commission 
ISO  International Organisation for Standardisation 
IVD  In Vitro Diagnostics 
LOD  Limit of Detection 
LOQ   Limit of Quantification 
MLPA  Multiplex Ligation-dependent Probe Amplification 
NIH  National Institutes of Health (USA) 
NIST  National Institute of Standards and Technology (USA) 
OECD  Organisation for Economic Cooperation and Development 
PAP  Pyrophosphorolysis-Activated Polymerization 
PCR  Polymerase Chain Reaction 
PHRED  PHRED is a base-calling program for automated sequencer traces 
QA  Quality Assurance 
QC  Quality Control 
QCM  Quality Control Material 
RM  Reference Material 
REMCO  ISO Committee on Reference Materials 
RFLP  Restriction Fragment Length Polymorphism 
SNP  Single Nucleotide Polymorphism 
VIM  International Vocabulary of Metrology - Basic and General Concepts and Associated 
Terms 
WHO  World Health Organization 
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1. Introduction 
 
Genetic tests can be highly predictive for the future health of the individual and can be 
carried out at any stage of life even in the embryo before implantation. They are relevant to 
healthy people as well as those showing symptoms of an unhealthy condition and may also 
have important implications for the relatives of the person tested. Given the rapid translation 
from research into clinical practice, research laboratories play a valuable role in service 
provision worldwide. The genotype established by a single laboratory test is usually not 
repeated and forms a permanent part of the medical record of the patient. Consequently, 
molecular genetic testing requires a high level of data reliability based on proper quality 
assurance of testing laboratories as well as of their measurement and testing procedures. As 
the field develops, the need for appropriate reference materials which are required to 
establish this reliability becomes increasingly urgent. The European Union (EU), the United 
States Food and Drug Administration (FDA) and National Institutes of Health (NIH), the 
Organisation for Economic Co-operation and Development (OECD), the World Health 
Organization (WHO), the Clinical Laboratory Standards Institute (CLSI) and other 
international bodies have realised the complexity of the problem and the importance of 
having rapidly clear guidelines addressed to the concerned parties. 
 
The EU regulates genetic tests through the in vitro diagnostic (IVD) medical devices Directive 
(98/79/EC) which covers commercial diagnostic tests, and the 92/42/EEC Directive on 
medical devices. The IVD Directive deals with all aspects of safety and performance, taking 
on board the need for common technical specifications such as sensitivity. Its main purpose 
is to introduce harmonised controls on IVDs throughout the EU. 
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2. Metrological Context and Terminology 
 
The metrological terms and specific vocabulary used in this document are summarised in 
Annex 1. 
 
The type of reference material (RM) which is required to perform a proper analysis of the 
sample of interest depends on the analytical problem. An analysis which is directed to 
qualitative properties of a sample (such as the chemical/biological identity of a sample 
component) needs a RM which allows comparison of this qualitative property in the sample 
and in the RM during the application of the same measurement or testing procedure. A 
typical example would be a RM consisting of plasmid DNA with a well defined base pair 
sequence used for the quality assurance of the DNA sequencing procedure of an unknown 
genomic DNA fragment. As the synthetic DNA RMs lack the complexity of the human 
genomic DNA and are sometimes designed to work with a dedicated platform, they might not 
perform identically to patient DNA. Therefore these materials have to be tested in ring trials, 
proficiency studies, or EQA schemes so that their fitness for purpose is demonstrated. 
On the other hand, most of the steps in quantitative measurements have to be calibrated 
because of the lack of completely known mathematical equations to calculate the relation 
between the targeted quantity in the sample and the measurement signal. Such calibration 
materials are almost indispensable for chemical and biochemical measurements. Moreover, 
reliable measurement results on the majority of the real-world samples can only be obtained 
if appropriate quality control measures are applied for most steps of the analytical process 
(Figure I). Therefore, so-called matrix RMs are developed which mimic as closely as possible 
the real sample (such as blood, bone marrow, amniotic fluid) and allow not only the control of 
the quantification step, but also of other steps such as sample preparation. 
 
The typical applications for RMs are:  
• method development and validation, in particular evaluation of trueness and 
evaluation of measurement uncertainty 
• calibration 
• proof of method performance, such as statistical quality control (via control charts 
etc.), establishing traceable results and qualification of equipment 
• proficiency testing, i.e. training and verification of the competence of laboratories 
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Figure I: Steps involved in the analytical process in general (left) and corresponding 
steps in genetic testing (right) 
 
 
 
 
 
 
 
 
Unfortunately a multitude of names is presently used for designation of RMs. Depending on 
the field of analytical activity, on the awareness of international guidelines, concepts of 
quality assurance and metrology and even on regional peculiarities one can find different 
terms for such RMs. Examples are: measurement standard, laboratory standard, reference 
standard, analytical standard, reference substance, standard material, quality control 
material, proficiency testing material, laboratory control material, laboratory reference 
material or calibration material. Part of the terminology confusion seems not only to originate 
from different traditions of the various analytical/measurement communities, but also from 
the different understanding of underlying concepts. For instance, the interrelation between 
the intended use for a RM in a given measurement procedure and the required minimum 
material characteristics together with the distributed RM information is often neglected. 
 
Recently the ISO Committee on Reference Materials (ISO REMCO) approved new 
definitions for "RM" and "CRM" (1). The term ‘reference material’ is now defined as follows: 
“Material, sufficiently homogeneous and stable with respect to one or more specified 
properties, which has been established to be fit for its intended use in a measurement 
process.  
NOTE  1:  RM is a generic term.  
NOTE 2: Properties can be quantitative or qualitative, e.g., identity of substances or 
species.  
NOTE 3: Uses may include the calibration of a measurement system, assessment of a 
measurement procedure, assigning values to other materials, and quality control.  
NOTE 4: A RM can only be used for a single purpose in a given measurement”. 
Sample preparation 
Conservation 
Evaluation 
Analyte identification 
 
& 
 
Quantitative measurement 
use of 
'qualitative’ 
 RM 
use of 
calibrant RM 
use of 
matrix 
 RM 
Cooling or freezing of the 
sample at 4 °C or -20 °C 
DNA extraction, purification 
Blood sampling, addition of 
anticoagulant, isolation of 
lymphocytes 
Compare results to data 
obtained with RMs or other 
available controls 
Presence of the genetic defect, 
diagnosis, prognosis 
PCR, sequencing, RFLP, 
MLPA, PAP, etc. 
 
& 
Real-time PCR, measurement 
of triplet repeats 
Sampling, Processing 
Assessment 
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The first note mentions now explicitly that the expression ‘reference material’ is an “umbrella 
term” for various materials which are needed in measurement procedures in addition to the 
sample to be analysed. Consequently one could consider the different RM types as members 
of a family (2). 
 
Obviously, all materials possessing the characteristics of adequate homogeneity and stability 
required for quality control of a given measurement belong to this RM family. The ones which 
are not accompanied by a certificate are often simply called non-certified RMs. But many 
other terms such as in-house materials, laboratory control materials or laboratory RMs are 
also used. Here the term “Quality Control Material (QCM)” is favoured for this subgroup of 
RMs for which only the material characteristics of homogeneity and stability fit for the 
intended use are proven. QCMs may support one or more applications from the wide range 
of both internal and external quality control measures. But they are not sufficiently 
characterised to be used for method calibration, trueness control or to provide metrological 
traceability of a measurement result. 
 
Another subgroup of RMs is formed by the certified RMs (CRMs). They are now defined as 
“reference material, characterised by a metrologically valid procedure for one or more 
specified properties, accompanied by a certificate that provides the value of the specified 
property, its associated uncertainty, and a statement of metrological traceability. NOTE 1: 
The concept of value includes qualitative attributes such as identity or sequence. 
Uncertainties for such attributes may be expressed as probabilities.  
NOTE 2: Metrologically valid procedures for the production and certification of reference 
materials are given in, among others, ISO Guides 34 and 35.  
NOTE 3: ISO Guide 31 gives guidance on the contents of certificates.”  
 
That means a RM belongs to this subgroup if in addition to the QCM characteristics a 
certificate is provided, giving a certified value with its uncertainty and a stated metrological 
traceability. Further details about these minimum quality characteristics of CRMs are 
explained in the corresponding ISO standards (3, 4, 5, 6, 7). 
 
The other RM subgroup is composed of the materials used for calibration. They are often 
denoted as analytical standards, reference standards or simply calibration materials, but 
usually not explicitly recognised as “reference materials”. Such products, in particular 
calibrants consisting of pure chemical substances or solutions thereof, are described by 
some scientists or organisations as having a “higher metrological order” than CRMs. This 
misperception originates from a mixing of classification systems. As regards the material 
characteristics necessary and the information provided, materials for calibration have to be 
sufficiently homogeneous and stable so as to ensure that the assigned property value and its 
uncertainty are valid for any calibration sample used according to the given specifications. 
Therefore, they fall under the RM definition given above and the term “calibrant” is used here 
for such materials. The necessary additional features of a calibrant in comparison to a QCM 
are a stated property value with an uncertainty and a metrological traceability of the property 
value. These characteristics are not always completely fulfilled by various materials 
nowadays used for calibration in different measurement communities or laboratories. This 
means only that insufficiently characterised materials are used for this purpose and it does 
not invalidate the principally required minimum quality characteristics for calibrants, in 
particular with respect to known uncertainty and traceability of the value used for calibration.  
 
For establishing harmonised references for measurement results of measurands for which 
their metrological traceability cannot be straightforwardly established to an independent 
measurement scale such as the SI, some measurement communities have started to set up 
so-called reference measurement systems. They are composed of reference methods, RMs 
and reference laboratories. To define and harmonise a measurement target, the respective 
organisation or network, such as IFCC (International Federation of Clinical Chemistry and 
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Laboratory Medicine) in the field of clinical and laboratory medicine, agrees on a common 
reference method. The measurand therefore is completely defined via the method. The 
measurand is not simply derived from a well defined molecular entity only (such as 
concentration of glucose in blood), but is defined as the signal obtained when a special set of 
instructions is followed. This has to be accompanied by one or more RMs which allow the 
installation of the corresponding reference method in the laboratory of interest and the 
performance of the method to be checked regularly. Most of these materials are CRMs, but 
there may be also sufficiently qualified RMs which do not officially come with a full certificate 
as described in ISO Guide 31 (8). Nevertheless these RMs could be qualified to be used at 
the highest metrological level which can be achieved for the time being. An illustrative 
representation of corresponding traceability chains for IVD is published and briefly discussed 
in ISO 17511 (7). The reference measurement system is completed by the establishment of 
reference laboratories that maintain the method performance and the production of the most 
accurate results achievable at present. 
 
Customers often do not fully use the potential of the purchased RM. One should realise that 
CRMs are not only a physical product in a bottle or ampoule, but that they are accompanied 
by important information on the material characteristics. CRMs which fulfil the requirements 
of ISO Guides 34 and 35 are delivered with a certificate which contains in addition to the 
certified value information about the uncertainty of the certified value and information about 
the metrological traceability. Moreover, this certificate includes instructions for use, storage 
conditions, expiration date of the certificate and either directly or via a link to other 
documents information about the procedures of its characterisation. The recommended 
content for CRM certificates is summarised in ISO Guide 31 (8). RM producers such as 
IRMM make an even more comprehensive description of the whole CRM preparation and 
certification process publicly available (www.irmm.jrc.be). 
 
It is self-evident that the user of a CRM does not have to care about the details of the CRM 
characterisation, if she/he can be confident that scientifically sound and internationally 
accepted approaches have been followed by the RM producer. However, it would be 
advisable that the user checks if this was indeed the case and if proper statements on 
metrological traceability and uncertainties of the certified values, which include all necessary 
components, are provided as information together with the material. With the increasing 
implementation of quality management systems and accreditation of testing laboratories, the 
critical consideration of the confidence in the producer of the RM used by a laboratory gains 
importance as well. Comparable to developments for the laboratory service of measurements 
during the last 10 years, there are now demands for demonstrated competence of RM 
producers through benchmarking against internationally agreed and harmonised criteria 
rather than accepting ‘designated’ competence largely based on self-declaration or traditional 
recognition. An increasing number of RM producers is seeking for accreditation according to 
ISO Guide 34. 
2.1. Fitness for purpose 
The suitability of a RM is based on the fact that the rigour with which an assessment needs 
to be conducted depends on the criticality of the measurement, the level of the technical 
requirement and the expected influence of the particular RM on the validity of the 
measurement. A formal suitability assessment is required only if the choice of a RM can be 
expected to affect the measurement results significantly. 
 
Factors to be considered include the following: 
1. The suitability of a RM depends on the details of the analytical specification. Matrix effects 
and other factors such as the concentration interval can be more important than the 
uncertainty of the certified value (9). 
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The factors to consider include: 
• Measurand  
• Measurement interval (concentration) 
• Matrix match and potential interferences 
• Sample size 
• Homogeneity and stability 
• Measurement uncertainty 
2. The validity of the ‘certification’ and uncertainty data, including conformance of key 
procedures with ISO Guide 35 and other ISO requirements (10, 11). 
3. Track record of both the producer and the material. For example, when a RM has been 
subjected to an interlaboratory comparison, cross-checked by different methods, or 
successfully used by a number of laboratories. 
4. Availability of a certificate and report conforming to ISO Guide 31. 
5. Demonstrated conformance of the production of the RMs with international standards such 
as ISO Guide 34 or corresponding international laboratory accreditation cooperation (ILAC) 
requirements (12), or compliance of the measurement of property values with ISO/IEC 17025 
(13) requirements. 
 
All or some of the requirements may be specified in the customer's analytical instruction 
sheet, but often it will be necessary for the analyst to use professional judgement. Finally, 
quality does not necessarily equate to small uncertainty and fitness for purpose criteria need 
to be used. 
2.2. Metrological Traceability 
Traceability of measurement results on a material is pivotal to the use of this material. 
Indeed, the planning of the measurements related to the characterization of the material 
depends on the standard to which traceability should be established and the means by which 
traceability will be established. To be able to establish traceability of a value to a certified 
value of a stated RM, all measurement results that are used for the assignment of this value 
(and its uncertainty) need to be traceable to this stated reference (Figure II). 
Three different kinds of traceability can be envisaged: 
 
- traceability to the international system of unit (SI): this option is the best as the values are 
independent of any validated method and artefact. They are universally valid. 
 
- traceability to a method: the values/properties assigned to the material are only valid when 
a specific measurement protocol is strictly followed. Note: when establishing traceability to a 
method of the results of a homogeneity or stability study, all measurements must be 
performed strictly according to the predefined measurement protocol of this method. As the 
analyte is defined via the method, results from other methods are not related to the assigned 
value/property. If any method other than the specific one has to be used, the reasoning why 
the result of this other method should be traceable to the result of the specific method must 
be laid down in the (certification) report. 
 
- traceability to an artefact (to a standard, to a particular instrument): this kind of traceability 
can be dependent or independent of a specific method. Note: when establishing traceability 
to an artefact independent of a method, it must be proven that the methods used in the 
homogeneity or stability study are validated, and that all measurement results are traceable 
to this artefact. The requirements for method validation include the following points: 
selectivity and interferences, correctness, and working range. When establishing traceability 
to an artefact dependent on a specific method, it must be proven that this specific method is 
used in the homogeneity or stability study, validated, and that all measurement results are 
traceable to this artefact. If any method other than the specific one has to be used, the 
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reasoning why the result of this other method should be traceable to the result of the specific 
method must be laid down in the (certification) report.  
 
By nature, the most common traceability statements to be achieved for genetic testing 
purpose are traceability to a method and to an artefact.  
 
Figure II: Schematic representation of a traceability chain 
 
 
 
In clinical chemistry, the term "value transfer" is used to denominate calibration of a property 
value in one material against the same property in another material. Different calibration or 
value transfer procedures are possible and depend on the availability of a suitable RM and 
its commutability within a measurement procedure (14). The characteristics of a RM for use 
in a value transfer are: 
- that characterisation of the material is such that it satisfies the definition of the measurand 
- that it possesses a sufficiently large property value to allow the assay of several dilutions 
within the working range of the method 
- that commutability/fitness for purpose has been proven 
- that validated stability and homogeneity of the material are available 
If these requirements are met, and the value transfer method is adequate, the target material 
can be traceable to the RM. 
primary reference 
measurement 
definition of 
(SI) unit 
secondary reference 
measurement 
manufacturer’s 
product calibrator 
end-user’s routine 
measurement 
routine sample 
RESULT 
manufacturer’s 
working 
primary calibrator 
manufacturer’s standing
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uncertainty 
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2.3. Estimation of bias  
Estimation of bias (the difference between the measured value and the true value) is one key 
element of method validation. Appropriate RMs can provide valuable information on that, 
within the limits of the uncertainty of the certified value(s) and the uncertainty of the method 
being validated. Clearly the RMs must be within the scope of the method in terms of matrix 
type, analyte concentration etc. and ideally a number of RMs covering the full range of the 
method should be tested. Where minor modifications to a well-established method are being 
evaluated then less rigorous bias studies (fewer replicates, larger range of concentrations) 
can be used. In addition, replicate measurements of the RM, covering the full range of 
variables allowed by the method being validated can be used to estimate the uncertainty 
associated with any bias (15). When a bias is detected, the cause should be investigated and 
if possible eliminated. If it cannot be eliminated a correction for the bias needs to be applied. 
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3. State of the Art 
3.1. In Vitro Diagnostic Medical Devices Directive (98/79/EC) 
The main purpose of the IVD Medical Devices Directive (98/79/EC), the Medical Devices 
Directive 93/42/EEC and the Active Implantable Medical Devices Directive 90/385/EEC, now 
implemented in the Member States, are to create a single market. This is done by introducing 
harmonised and statute-based controls to regulate the safety and performance of medical 
devices throughout the EU. 
 
A medical device is defined as "any instrument, apparatus, appliance; material or other 
article, whether used alone or in combination, including the software necessary for its proper 
application; intended by the manufacturer to be used on human beings for the purpose of:  
 -  diagnosis, prevention, monitoring, treatment or alleviation of disease, 
 - diagnosis, monitoring, treatment; alleviation of or compensation for an injury or 
handicap, 
 - investigation, replacement or modification of the anatomy or of a physiological 
process, 
 - control of conception; 
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its 
function by such means". 
 
The term in vitro diagnostic medical device refers to "any medical device which is a 
reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment, 
or system, whether used alone or in combination, intended by the manufacturer to be used in 
vitro for the examination of specimens, including blood and tissue donations, derived from 
the human body, solely or principally for the purpose of providing information: 
 - concerning a physiological or pathological state, or 
 - concerning a congenital abnormality, or 
 - to determine the safety and compatibility with potential recipients, or 
 - to monitor therapeutic measures". 
 
The CE mark grants that the device satisfies the relevant essential requirements, that it is fit 
for its intended purpose as specified by the manufacturer, and that the product can be freely 
marketed anywhere in the EU without further control. 
3.2. Patent issues related to RMs for genetic testing  
The European Directive 98/44/EC allows gene patents under certain circumstances as 
specified in Article 9: "The protection conferred by a patent on a product containing or 
consisting of genetic information shall extend to all material in which the product is 
incorporated and in which the genetic material is contained and performs its function." The 
patent law specifies the acts that are prohibited to third parties (which could mean those 
developing, producing or using RMs). Generally, the patent owner has the right to prevent 
any third party from making, using, offering for sale, selling or importing the patented product. 
The actual meaning of patent claims is ultimately decided by the courts. There are no 
general patent rules for the production of a reference material for genetic testing and it is 
common to proceed on a case by case basis. 
 
The use of short sequences from a gene patented for its expression of a novel protein will 
not infringe the patent, as in this particular case the function of the novel protein is patented 
and not the shorter DNA fragments of that gene. But patents on gene sequences can create 
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a barrier to producing RMs. It is always advisable to verify the territoriality of the patent and 
its expiration date, or to get a licence from the patent owner. 
 
One way to prevent the patenting of newly-discovered genes, newly-developed genetic tests 
or newly-characterised RMs that can be important for public health is to put the information 
into the public domain, e.g. by publication in a scientific journal. 
3.3. The EuroGentest project 
EuroGentest is an international Network of Excellence funded by the European Commission 
which is looking at various aspects of genetic testing - quality management, information 
databases, public health, ethics and legal issues, new technologies and education. 
EuroGentest aims at test development, harmonization, validation and standardization for 
genetic testing in Europe. As technologies used for molecular genetic testing begin to enter 
the mainstream of clinical practice, the need for appropriate RMs that could guarantee the 
development, validation and harmonisation of these methods becomes increasingly urgent. 
Accordingly, EuroGentest partners from the EU and the Centers for Disease Control and 
Prevention (CDC) of the USA met in two International Symposia on Reference Materials for 
Genetic Testing in 2005 and 2007 to discuss key issues such as regulations, current RM 
availability, development and prioritisation of future needs. The present document contributes 
to the deliverables of the work package 1.6 of Unit 1 dealing with reference systems. 
3.4. OECD position 
The Organisation for Economic Co-operation and Development (OECD) has proposed 
Guidelines for Quality Assurance in Molecular Genetic Testing (16). The Guidelines offer 
principles and best practices for human genetic testing by encouraging high quality 
laboratory practices in the collection and handling of samples and data, result reporting, 
education and training. They address genetic testing for variations in germ line DNA 
sequences or products arising directly from changes in heritable genomic sequences that 
predict effects on the health, or influence the health management, of an individual. They 
focus on molecular genetic testing for the diagnosis of a particular disease or condition and 
predictive genetic testing often carried out before any clinical signs of the disease or 
condition appear. They are relevant to tests for heritable DNA variants that predict the 
response profile of an individual to a drug or course of therapy and that affect susceptibility to 
disease, patient prognosis, counselling, treatment and family planning. Besides accreditation 
that can guarantee quality assurance, the guidelines encourage as well the validation of the 
tests to be performed, the monitoring of the quality of laboratory performance using 
proficiency testing schemes, the quality of test results reporting and the education and 
training for laboratory personnel. 
 
In addition, parts of these guidelines are also relevant and applicable to aspects of clinical 
cytogenetics testing and biochemical genetic testing. However, they are not designed to 
address directly the areas of testing for somatic mutations, variants important in tissue 
matching, genetic analysis of pathogenic organisms and identity testing, though all share 
related technologies.  
 
In conclusion, the guidelines are meant to encourage quality assurance systems for human 
genetic and genomic testing, guarantee the international exchange of clinical samples and 
access to data on rare disease testing. The ethical and legal principles set out in international 
declarations and agreements and the diversity of national jurisdictions have been recognised 
during their development. 
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3.5. Availability of Reference Materials  
The availability of CRMs is a prerequisite for a thorough method validation and supports the 
development of reliable commercial genetic testing kits. In general RMs are essential for 
internal quality control and the performance of External Quality Assessment schemes (EQA), 
including the monitoring of test performance, the detection of errors in the testing procedure 
and the validation of any test intended for patient testing. Analysis of appropriate positive and 
negative samples for the genotype to be detected can establish or verify sensitivity, 
specificity, and other performance characteristics for the test.  
 
The basic requirement for routine testing is to include well-characterised positive and 
negative samples in each run of patient specimens. Presently, most genetic tests are 
developed in-house by individual laboratories and therefore harmonisation of the control 
samples and of the measurement procedures is needed.  
 
The final goal of a genetic test is the potential identification of variants or abnormalities in a 
nucleic acid sequence such as mutation(s), translocation(s), duplication, amplification and 
deletion(s). With the exception of copy number variations, the quantification of the target 
sequence modification is not needed as the expected diagnostic result consists of a yes/no 
answer about the presence or absence of the modification. Therefore potential RMs have to 
provide (certified) properties which are more of "qualitative" than "quantitative" nature. High 
quality materials with a certified DNA sequence, for which homogeneity among the 
molecules, stability and commutability or suitability of the materials have been proven, are 
required. At present the availability of RMs for genetic testing is rather limited. 
Examples of available CRMs for genetic testing are the three RMs produced by IRMM (EC) 
for the human Prothrombin/Factor II G20210A mutation detection (plasmids).  
Other CRMs available from NIST (USA) (called standard reference materials by NIST) are 
the Fragile X human DNA triplet repeat standard RM 2399 and Human Y-chromosome DNA 
profiling standard RM 2395 (NIST).  
NIBSC (GB) has also produced several materials (called international standards) for genetic 
testing on behalf of WHO, but the homogeneity of those has not been tested. Therefore, 
although the stability of these materials was tested via accelerated degradation schemes (up 
to 6 months storage at 45 °C and 56 °C), they cannot be called RMs according to the 
definition stated in ISO Guide 34 (3). 
CDC (USA) coordinates a program for the development and the characterisation of cell lines 
derived from patients' blood suffering from various genetic diseases and provides either the 
cell lines, or a dried cell pellet as RM. 
Other private companies (MMQCI, Roche, etc.) have also developed controls in their kits for 
testing but the requirement of stability and homogeneity testing is not always met. 
 
The EuroGentest website (www.eurogentest.org) lists several RM producers and available 
products for genetic testing. 
3.6. Conclusion 
Genetic testing is a burning issue as the results of the tests can have consequences not only 
for the individuals tested but also for their relatives. Therefore legal and ethical 
considerations are applicable (regulated, among others, by the IVD Directive 98/79/EC in 
Europe). In addition, appropriate quality assurance of the testing is a pre-requisite for 
achieving confidence in the results within and between laboratories. Quality management 
and harmonisation of the tests are investigated in Europe by the NoE EuroGentest and the 
OECD has recently issued guidelines for quality assurance in molecular genetic testing (16). 
Although the field of genetic testing is evolving rapidly, the availability of RMs required for 
method development and validation is still limited. 
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4. Selection criteria for reference materials according to 
their use 
General guidance is provided, among others, in ISO Guides 32 (17) and 33 (18) and 
Eurachem CITAC Guide (19). Therefore, only the main aspects and some specific 
recommendations are summarised hereafter and in Annex 2. 
4.1. Method Development and Validation 
The successful installation of a new method in a laboratory includes the following steps: 
method development, implementation, validation and performance monitoring. It is necessary 
to establish that the signal produced at the measurement stage or other measurement 
property, which has been attributed to the analyte, is only due to the analyte and not to the 
presence of a chemically or physically similar entity. This is confirmation of identity. Whether 
or not other components will interfere with the measurement of the analyte will depend on the 
effectiveness of the isolation stage and the specificity of the measurement stage. A method 
should be validated to verify that its performance parameters are adequate for use for a 
particular analytical problem. Some validation protocols confuse confirmation of identity with 
repeatability. Whereas evaluation of repeatability requires the measurement to be performed 
several times by one technique, confirmation of identity requires the measurement to be 
performed by several, preferably independent techniques. 
Method validation gives an idea of a method's performance capabilities and limitations which 
may be experienced in routine use while the method is in control (that is the method is 
performing the way expected).  
4.2. Diagnostic Tests Development and Validation 
In the case of diagnostic tests for genetic testing, one can identify different phases:  
- a design phase including a review of the literature, of the clinical utility of the test, a detailed 
description of the method, the required staff and the necessary equipment 
- a production phase describing the product specifications, the environmental conditions that 
might influence its integrity 
- an initial technical validation phase including the use of RMs and/or of reference 
measurement procedures (e.g. for verification of patient status), determination of the 
uncertainty (if applicable), method specificity and sensitivity 
- a permanent quality monitoring phase that reviews annually the performances and 
properties of the product, for instance using an EQA scheme and/or regularly RMs. 
4.3. Calibration (for quantitative methods) 
Normally a pure substance RM is used for calibration of the measurement stage of a method. 
Other components of the test method, such as sample preparation, are not covered. Loss of 
analyte, contamination and interferences and their associated uncertainties must be 
addressed as part of the validation of the method, for example using an internal standard. 
The uncertainty associated with the RM purity will contribute to the total uncertainty of the 
measurement. In the field of genetic testing, purified plasmidic or genomic DNA can be 
considered as pure substance calibrant. 
 
The use of matrix RMs for calibration of the complete analytical process constitutes a 
scenario close to real samples, but the most important aspect is that the analyte in RMs must 
be in a form which behaves similar in the measurement procedure to the real samples (20). 
However, RMs from the same source should not be used at the same time for calibration and 
the ongoing assessment of a measurement procedure. Using the same RM for both 
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applications would create a vicious circle and would not allow the identification of calibration 
errors. For this reason, the ISO Guide 35 states that a RM can only be used for a single 
purpose in a given measurement (4). 
The ISO Guide 32 and reference (11) provide additional useful information. 
4.4. Quality Assurance and Quality Control (QA & QC) 
Materials for statistical quality control are used for a longer period of time to allow 
conclusions about the performance and potential changes of a method or the laboratory 
personnel to be drawn from control charts. RMs used in this case should be characterised 
with respect to homogeneity, stability, and their property value(s). Similar requirements apply 
to samples used to establish how measurements made in different laboratories agree.  
 
In the case of proficiency testing, homogeneity of the distributed subsamples is essential and 
sample stability within the time-scale of the exercise must be assessed and controlled.  
4.5. Interlaboratory studies 
Each interlaboratory study includes the distribution of various units of samples to a group of 
participants. Such studies are organised for proficiency testing of laboratories, method 
validation or method standardization or characterization of candidate RMs. The homogeneity 
of the materials used for such exercises is crucial as variations of results should only reflect 
the reproducibility of the method(s) and not the suitability of the material as reference. 
4.6. Identity checks 
In the case of the identification of a nucleic acid sequence, DNA sequencing can be 
considered as one of the more robust methods. For validation purposes, attention should be 
paid that the sequence of interest has been obtained using forward and backward 
sequencing primers spanning the same target region. The uncertainty can then be expressed 
as the probability of misreadings in the sequence of nucleic acids in the target, for example 
using a PHRED score.  
4.7. In-house RMs 
If commercial RMs are not available for the specific user need, one has to consider to 
prepare a RM internally. There are guides available (20, 21) to help the non-specialist 
laboratory to prepare their own RMs. Some of the key issues that need to be considered are: 
selection of materials (appropriateness, native material versus spikes, material preparation 
etc.), homogeneity testing, preparation and packaging (homogeneity, contamination, stability 
etc.), stability testing, characterisation studies, uncertainty estimation, documentation and 
QA, storage and further stability monitoring. 
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5. Application Guidance 
Some of the frequently asked questions concerning DNA-based RMs and their answers are 
listed in Annex 3. 
5.1. Quantitative measurements 
As mentioned previously, in the field of genetic testing, most applications are qualitative. 
However, the assessment of copy numbers of nucleic acid sequences revealing the 
presence of a gene amplification or deletion, of contaminating micro-organisms, of a residual 
disease (as in cancer monitoring) or the number of trinucleotide repeats in a gene (such as in 
the Fragile X disease) can be considered as quantitative applications.  
 
The determination of the copy number, length or size of a nucleic acid sequence in a gene 
should be performed according to the guidelines given above and the results must include a 
stated uncertainty determined by statistics and the associated traceability chain. Some of the 
methods involved are real-time PCR, fluorescence in situ hybridization and sequencing.  
 
Every property value assigned to a RM must be accompanied by a statement on its 
metrological traceability. The uncertainty linked to an assigned value consists of contributions 
from homogeneity, stability and characterization studies. Each contribution is estimated 
individually and the squared contributions should be combined. An example of quantitative 
assessment of nucleic acid sequence copy number can be found in the literature (22) where 
the use of genomic and plasmid DNA were compared for the assessment of the DNA copy 
number ratio in matrix-based genetically modified organisms-derived CRMs. 
The measurement uncertainty is linked to the individual measurement performed but not to a 
defined method as such. The uncertainty arises from both sampling and analysis, unless it 
could be that the sampling carried out is representative and that the sampling uncertainty can 
therefore be neglected. Two approaches can be followed in order to determine the 
contribution to measurement uncertainty: either considering all the individual uncertainties 
resulting from the individual steps involved in the measurement (i.e. DNA extraction, PCR 
reaction, calibration, analysis of results), or taking into account the data obtained from the 
method validation and quality assurance (i.e. repeatability, reproducibility, interlaboratory 
comparison). A detailed description of the second approach for the estimation of the 
measurement uncertainty using real-time PCR measurements is provided in (23). 
 
Moreover, for quantitative results, the following steps should be followed in order to compare 
one's own measurement result with the certified value of a CRM. 
The underlying principle is that one has to check whether the difference between the 
measured result and the certified value is larger than the expanded combined measurement 
uncertainty and certified value.  
This is done as follows:  
1. Calculate the standard uncertainty of the certified value (uCRM).  
This is done by dividing the expanded uncertainty given on the certificate by the coverage 
factor (also stated on the certificate).  
2. Estimate the measurement uncertainty (um) of the result. As a very rough approximation, 
the reproducibility standard deviation can be used.  
3. Combine the two uncertainties using the following formula:  
 
4. Check whether 2*uc is larger than the difference between the certified and the 
measurement value. If this is the case, the measurement result agrees within the limits of the 
respective uncertainties with the certified values. 
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See http://www.irmm.jrc.be/html/reference_materials_catalogue/user_support/use.htm] 
5.2. Qualitative measurements 
Guidelines from EURACHEM/CITAC are under development for these types of 
measurements (24). For qualitative measurements in genetic testing, the uncertainty can be 
expressed as a probability of obtaining a mistake/misreading of a base in the sequence. The 
calculation of this probability will depend on the measurement procedure and it should be as 
low as possible. 
In most cases, genetic testing consists in the assessment of the presence or absence of 
specific nucleotide sequence(s) using analytical methods that focus on sequence identity or 
property rather than quantity. 
 
As an example, if bi-directional sequencing has been used for identification of a 500 bp DNA 
fragment, the probability of misreadings in the sequence as a first estimate could be 
calculated theoretically as 1/500 * 1/500 = 4 10-6. This probability could be reduced further by 
sequencing the sample molecules backwards and forwards several times and on different 
platforms. Therefore, an internal control with a well characterised or better with a certified 
sequence (such as a commercially available plasmid vectors) should always be run in 
parallel to the sequencing reaction of the samples. After analysis, the results should then be 
compared to the corresponding sequences available in databases in order to identify the 
variants and to estimate the trueness of the measurement result.  
Although sequencing is a time-consuming and expensive method as compared to other 
genotyping procedures, it is still quite robust (25-27), and remains the reference method in 
case of dubious results. The other methods used for genotyping (RFLP, Southern Blotting, 
PCR-derived methods for allelic discrimination, real-time PCR, MLPA, PAP, etc.) focus on 
shorter sequences and allow only the characterisation of the small fragments amplified. 
For DNA sequencing to become widely accepted as a reference method for SNPs, uniform 
DNA samples would have to be dispatched to several labs for sequencing, and the results 
should be similar using different platforms and chemistries on different days to fulfil 
internationally accepted requirements for the validation of reference methods. However, for 
the experimental determination of the probability of sequencing failures under the 
requirement of matching forward and backward sequencing, a very large number of 
sequencing experiments would have to be carried out to detect the expected low number of 
matching misreadings. 
Considering that other genetic variations could be difficult to identify by sequencing, there 
would not be only one reference method for genetic testing but several, depending on the 
defect to be identified. The most important characteristic is that the method would be robust 
and not affected by small changes such as temperature, pH, etc., and validated using RMs 
for which the target DNA sequence concentration is in the range of what can be expected in 
the case of real samples. In addition, this method should have been tested using 
interlaboratory comparison studies. 
 
5.3. Highlights of important aspects for good QC in a genetic testing 
laboratory 
 
Recommendations can be found in the standards ISO 15189 and 17025 which are the basis 
for accreditation of laboratories. The following recommendations can only be used for the 
period in which the laboratories are preparing for accreditation. The referral to the OECD 
principles of Good Laboratory Practice (28) that establish the minimum quality assurance 
requirements necessary to ensure the validity of experimental results can also be useful in 
this respect. 
The following is recommended: 
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1. A laboratory responsible/manager/director should be designated in order to co-ordinate 
the activities of the laboratory and personnel. 
 
2. Installing a new instrument/new test method in the laboratory: 
Upon arrival of a new instrument, an instrument file in which all related documents such as 
maintenance, problems, authorised users, performance qualification, etc. should be prepared 
as well as a work instruction for its operation. This standard operating procedure or work 
instruction will describe its aim and scope, as well as the definitions, the description, and the 
necessary steps related to maintenance, safety and responsabilities for the instrument. In 
particular, an instrument qualification (performed to make sure that the instrument was 
properly installed), and a calibration/operation qualification (to check whether the instrument 
is fit for its intended purpose and works according to specifications) will have to be performed 
and documented. The instrument qualification needs only to be repeated if the instrument 
has been moved or if there is some other significant change in the instrument's environment. 
The operation qualification should be performed regularly, as specified in the work 
instruction. A logbook should be associated to the instrument so that all performed analyses 
are recorded, as well as potential problems, calibrations, maintenance, etc. 
Forms for sample analyses and associated to the work instruction can be prepared so that all 
parameters of the related experiment are registered.  
If new methods are introduced in the laboratory, they should be validated, this includes 
determination of method performance parameters such as LOD, LOQ, linearity/working 
range (if applicable), repeatability, robustness, specificity, sensitivity, trueness (see also 
section 3.1 for validation of diagnostic tests). 
 
3. Introducing new laboratory personnel: 
Training on the instrument will have to be organised for the concerned staff. 
The personnel that should operate the instrument will have to demonstrate their ability by 
measuring a RM with the required specificity and sensitivity, and, in case of quantitative 
measurements, for establishing analytical performance parameters such as LOD, LOQ, 
trueness,...Therefore, blinded CRM samples should be distributed and the supervising staff 
should compare the obtained results with the certified values (and their uncertainties). 
 
4. Routine operation of the lab: 
Once the method(s) has been validated and the instrument is operational, a control chart can 
be established by using QC samples (for which homogeneity and stability have been proven) 
available in sufficient quantities for repetitive analysis. The random variation in performance 
of the analytical method can be monitored by monitoring the analysed value of the QC 
sample, usually by plotting it in a control chart. Limits are set for the values on the chart 
(conventionally 'warning limits' are set at +/- 2σ around the mean value, and 'action limits' are 
set at +/- 3σ around the mean value). Each run should include an internal positive and 
negative control sample in order to assess the regular QC of the method. In addition, it would 
be advisable to measure regularly (every 100th sample for instance or after a defined time 
period) a RM sample in order to compare the obtained results with the certified (assigned) 
RM value and introduce the measurement result in the control chart. 
Major deviation of measurement results from the expected values/properties should be 
carefully scrutinised, investigated, recorded and reported to the laboratory 
responsible/director/manager. 
 
5. The laboratory should participate regularly (when the possibility is offered by an EQA 
organizer) in an interlaboratory/proficiency testing exercise and demand from the provider a 
thorough evaluation of their performance afterwards. 
 
6. The analysis requests, the reporting of the results and the retention of the records and the 
materials for a certain period should be guaranteed. 
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ANNEX 1: Selected definitions relevant to genetic testing 
 
Accuracy 
The closeness of agreement between a test result and the accepted reference value.  
 
Analyte 
Component represented in the name of a measurable quantity. 
 
Bias 
Difference between the mean measured value from a large series of test results and an 
accepted reference value (a certified or nominal value). The measure of trueness is normally 
expressed in term of bias. 
 
Calibrant/Calibrator 
The necessary additional features of a calibrant in comparison to the general RM 
characteristics are identical to the ones of the certified reference material, except that the 
production of a certificate is optional. Calibrants should come with property values with 
sufficiently small measurement uncertainties and are used for direct calibration or other value 
transfer operations. 
 
Calibration (VIM, 2007) 
Operation that, under specified conditions, in a first step establishes a relation between the 
quantity values with measurement uncertainties provided by measurement standards and 
corresponding indications with associated measurement uncertainties and, in a second step, 
uses this information to establish a relation for obtaining a measurement result from an 
indication. 
Notes:  1) A calibration may be expressed by a statement, calibration function, calibration 
diagram, calibration curve, or calibration table. In some cases it may consist of an additive or 
multiplicative correction of the indication with associated measurement uncertainty. 
 2) Calibration should not be confused with adjustment of a measuring system, often 
mistakenly called "self calibration", or with verification of calibration. 
 3) Often, the first step alone in the above definition is perceived as being calibration. 
 
Certificates and Supporting Reports 
Ideally, a certificate complying with ISO Guide 31 and a report covering the characterisation 
and certification procedures, complying with ISO Guide 35, should be available for the 
certified reference materials. However, many RMs may not fully comply with ISO Guides 31 
and 35 but equivalent information is available, providing credible evidence of compliance and 
can be considered as acceptable. Examples include the following: technical reports, trade 
specifications, papers in journals or reports of scientific meetings and correspondence with 
suppliers. 
 
Certified Reference Material (CRM, ISO Guide 35, 2006 amended) 
A RM characterised by a metrologically valid procedure for one or more specified properties, 
accompanied by a certificate that states the value of the specified property, its associated 
uncertainty, and a statement of metrological traceability. 
 
Notes: 1) The concept of values includes qualitative attributes such as identity or sequence. 
Uncertainties for such attributes may be expressed as probabilities. 
 2) Metrologically valid procedures for the production and certification of reference 
materials are given in among others ISO Guides 34 and 35. 
 3) ISO Guide 31 gives guidance on the contents of certificates. 
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Commutability  
1. Closeness of agreement between the mathematical relationship of the measurement 
results obtained by two measurement procedures for a stated quantity in a given material, 
and the mathematical relationship obtained for the quantity in routine samples (ISO 17511, 
2003). 
 
2. Property of a given RM demonstrated by the closeness of agreement between the relation 
among the measurement results, for a stated quantity in this material, obtained according to 
two given measurement procedures, and the relation obtained among the measurement 
results for other specified materials (VIM 2007). 
Note: The material in question is usually a calibrator, and at least one of the two given 
measurement procedures is usually a high-level measurement procedure. Therefore, one 
important application of a commutable reference material is assigning values to other 
materials. 
3. Working definition: the equivalence of mathematical relationships between the results of 
different measurement procedures for a reference (or control) material and for native clinical 
samples. 
 
Genetic testing  
The UNESCO definition from the International Declaration on Human Genetic Data was used 
in this document, as the Network of Excellence EuroGentest is currently working on a 
definition. "A procedure to detect the presence or absence of, or change in, a particular gene 
or chromosome, including an indirect test for a gene product or other specific metabolite that 
is primarily indicative of a specific genetic change". 
 
Limit of Detection (LOD)  
Limit of detection is the lowest concentration or content of the analytes that can be detected 
reliably, but not necessarily quantified. LOD is generally expressed as the amount of analyte 
at which the analytical method detects the presence of the analyte at least 95% of the time (< 
5% false negative results).  
 
Limit of Quantification (LOQ)  
The limit of quantification of an analytical procedure is the lowest amount or concentration of 
analyte in a sample, which can be quantitatively determined with an acceptable level of 
precision and accuracy.  
 
Measurand (VIM, 2007) 
The measurand is defined as the quantity intended to be measured.  
In genetic testing, it could be interpreted as the presence of a particular DNA sequence in the 
patient's blood. However, due to the various steps required during the analysis of the DNA 
(starting from the DNA extraction procedure from blood to further analysis such as PCR, 
RFLP or sequencing), the target actually measured at the final stage of analysis might differ 
from the one intended to be measured at the beginning as byproducts or impurities might 
have been added/removed from the original blood sample during the analytical procedure. 
 
Measurement Uncertainty  
Parameter, associated with the result of a measurement, that characterises the dispersion of 
the values that could reasonably be attributed to the measurand. 
 
Notes:  1) The parameter may be, for example, a standard deviation (or a given multiple of it), 
or the half-width of an interval having a stated level of confidence. 
2) Uncertainty of measurement comprises, in general, many components. Some of 
these components may be evaluated from the statistical distribution of results of a series of 
measurements and can be characterised by experimental standard deviations. The other 
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components, which can also be characterised by standard deviations, are evaluated from 
assumed probability distributions based on experience or other information. 
3) It is understood that the result of a measurement is the best estimate of the value 
of a measurand, and that all components of uncertainty, including those arising from 
systematic effects, such as components associated with corrections and reference 
standards, contribute to the dispersion. 
 
Metrological Traceability (VIM, 2007) 
Property of a measurement result whereby the result can be related to a stated metrological 
reference through a documented unbroken chain of calibrations, each contributing to the 
measurement uncertainty 
 
Notes:  1) For this definition, a ‘stated metrological reference’ can be a definition of a 
measurement unit through its practical realization, or a measurement procedure including the 
measurement unit for a non-ordinal quantity, or a measurement standard. 
2) Metrological traceability requires an established calibration hierarchy. 
3) Specification of the reference must include the time at which this reference was 
used in establishing the calibration hierarchy, along with any other relevant metrological 
information about the reference, such as when the first calibration in the calibration hierarchy 
was performed. 
4) For measurements with more than one input quantity to the measurement model, 
each of the input quantities should itself be metrologically traceable and the calibration 
hierarchy involved may form a branched structure or a network. The effort involved in 
establishing metrological traceability for each input quantity value should be commensurate 
with its relative contribution to the measurement result.  
5) Metrological traceability of a measurement result does not ensure that the 
measurement uncertainty is adequate for a given purpose or that there is an absence of 
mistakes. 
6) A comparison between two measurement standards may be viewed as a 
calibration if the comparison is used to check and, if necessary, correct the quantity value 
and measurement uncertainty attributed to one of the measurement standards. 
7) The ILAC considers the elements for confirming metrological traceability to be an 
unbroken metrological traceability chain to an international measurement standard or a 
national measurement standard, a documented measurement uncertainty, a documented 
measurement procedure, accredited technical competence, metrological traceability to the 
SI, and calibration intervals (see ILAC P-10:2002). 
8) The abbreviated term ‘traceability’ is sometimes used to mean ‘metrological 
traceability’ as well as for other concepts, such as ‘sample traceability’ or ‘document 
traceability’ or ‘instrument traceability’ or ‘material traceability’, where the history (‘trace’) of 
an item is meant. Therefore, the full term of ‘metrological traceability’ is preferred if there is 
risk of confusion. 
 
Reference Material (RM, ISO Guide 35, 2006) 
Material, sufficiently homogeneous and stable with respect to one or more specified 
properties, which has been established to be fit for its intended use in a measurement 
process. 
Notes: 1) RM is a generic term. 
 2) Properties can be quantitative or qualitative, e.g.  identity of substances or species. 
 3) Uses may include the calibration of a measurement system, assessment of a 
measurement procedure, assigning values to other materials, and quality control. 
 4) A RM can only be used for a single purpose in a given measurement. 
 5) A distinction between "pure substance" RMs and "matrix" RMs can be made. 
Matrix RMs for laboratory medicine are basically blood, urine, serum or other tissue samples 
which have been processed to reference material. The matrix is colloquially the surrounding 
substance around the analyte. 
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Sensitivity  
The sensitivity of a method is a measure of the magnitude of the response caused by a 
certain amount of analyte. 
The method should be sensitive enough in order to be able to detect/quantify with respect to 
the thresholds as provided in the relevant legislation.  
Since sensitivity is method- and purpose-dependent it should be specified in the protocol. A 
reasonable goal for sensitivity is that required to meet levels specified in contracts, with a 
reasonable certainty that the level does not exceed the required limit.   
Sensitivity as a term is used in two different ways - LOD and the slope of a curve. The use of 
the LOD is the preferred term to use as a measure of the ability of a method to detect a small 
amount of analyte. 
 
Specificity 
Property of a method to respond exclusively to the characteristic or analyte of interest.  
 
Trueness  
The closeness of agreement between the average value obtained from a large series of test 
results and an accepted reference value. 
 
Validation 
Verification, where the specified requirements are adequate for an intended use. 
Example: A measurement procedure, ordinarily used for the measurement of mass 
concentration of nitrogen in water, may be validated also for measurement in human serum. 
 
Verification 
Provision of objective evidence that a given item fulfils specified requirements 
Examples:  1. Confirmation that a given reference material as claimed is homogeneous 
for the quantity value and measurement procedure concerned, down to a measurement 
portion having a mass of 10 mg. 
  2. Confirmation that performance properties or legal requirements of a 
measuring system are achieved. 
  3. Confirmation that a target measurement uncertainty can be met. 
 
Notes:  1) When applicable, measurement uncertainty should be taken into consideration. 
2) The item may be, e.g.;, a process, measurement procedure, material, compound, 
or measuring system. 
3) The specified requirements may be, e.g.; that a manufacturer's specifications are 
met. 
4) Verification in legal metrology, as defined in VIML, and in conformity assessment in 
general, pertains to the examination and marking and/or issuing of a verification certificate for 
a measuring system. 
5) Verification should not be confused with calibration. Not any verification is a 
validation. 
6) In chemistry, verification of identity of entity involved, or of activity, requires a 
description of the structure or properties of that entity or activity. 
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ANNEX 2: Minimum Quality requirements for various types of reference materials 
 
Intended Use 
 
 
Material 
characteristics 
Method development 
and validation 
Interlaboratory 
comparison 
Statistical quality control Real sample to be 
analysed 
Matrix/concentration 
matching with real 
samples 
As close as possible to 
real sample 
Analyte/matrix combination 
as available in existing PT 
schemes 
Matrix type should be comparable  
Minimum sample 
intake 
Tested and found 
smaller than necessary 
for the tested method 
Tested and found smaller 
than all of the methods 
potentially used 
Tested and found smaller than the 
sample intake of the method 
Sufficiently small for 
the method used 
Between-unit 
homogeneity 
 Tested and found to 
contribute negligibly to 
uncertainty 
Tested and found to contribute 
negligibly to uncertainty 
Not applicable 
Stability during 
transport 
 Tested and potential 
degradation during 
transport found negligible 
 Stable from sampling 
to the laboratory 
Stability during 
storage 
Tested and found stable 
during the duration of 
the study 
Tested and found stable 
during the duration of the 
study 
Long-term stability necessary Stable for the duration 
of the analysis 
Assignment of 
traceable values 
with uncertainty 
Allows assessment of 
accuracy for method 
validation 
Reference for traceability 
must be useful, uncertainty 
must be smaller than 
measurement uncertainty 
At least a value traceable to the 
method must be assigned 
 
Certification Guarantees above 
characteristics 
Allow repetition of the study 
and constitutes reference 
for evaluation 
Allows not only evaluation of trends 
but also an assessment of accuracy 
with every use 
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ANNEX 3: Questions specifically related to DNA-based 
CRMs for genetic testing 
 
 
Where do I get instructions on how to perform a PCR? 
 
The description of specific detection methods is available in the literature. Detection methods 
used during the certification of a CRM are listed in the certification report. An example of 
certification of a RM for genetic testing for the G20210A mutation in the prothrombin/FactorII 
can be found at the following address and typing as RM code 490 (wildtype sequence), 491 
(G20210A mutant) or 492 (heterozygous G20210A) 
(http://www.irmm.jrc.be/rmcatalogue/searchResultrmcatalogue.do). 
 
Which DNA extraction method should I use? 
 
Reliable results can only be guaranteed if an extraction method validated in a collaborative 
trial is used. Be aware that some extraction methods might generate inhibitors that can 
impair the subsequent detection reaction(s). 
 
Is the sequence information corresponding to the genetic disease publicly
available? 
 
The wild-type sequence of a gene is in general accessible in the public database such as 
GenBank (www.ncbi.nlm.nih.gov), whereas the primer and probe sequences that target the 
specific region to be checked might be confidential or published and publicly available (in 
PUBMED for instance at www.ncbi.nlm.nih.gov). The sequence information of a gene might 
be patented in some countries, especially if the function of the gene is known. However, in 
some cases, the information can be used for public health reasons.  
 
 Are there reference materials available for the genetic test I am planning to perform?
 
There are several RMs producers such as IRMM, NIBSC, NIST, CDC, and private 
companies. Consult the EuroGentest website (www.eurogentest.org) to find useful links to 
RMs available and their producers. 
 
How do I choose a RM for the genetic testing according to its formulation/presentation
(according to CRMGEN project, FP5-funded project)? 
 
Type Similar to 
usual 
samples 
Versatile Stable Economical 
to produce 
Storage 
Cost 
Ethical 
issues 
Cell Line +++ +++ - + - + 
Genomic DNA ++ ++ + ++ ++ + 
Recombinant DNA + ++ ++ +++ ++ ++ 
PCR Product + ++ ++ +++ ++ ++ 
Synthetic DNA - - ++ ++ ++ +++ 
Key: +++, excellent; ++, very favourable; +, moderate; -, less favourable 
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